Go back to the main page.
Transforming Today's Science Into Tomorrow's Cures
Samaritan's collaborative researchers have made important patented discoveries in the fields of, central nervous system diseases, such as, Alzheimer's disease; cancer; cardiovascular disease; and infectious diseases, such as, AIDS, and Hepatitis C. These discoveries have positioned us with a rich pipeline of new drugs with novel mechanisms of actions to develop.
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company focused on the development and marketing of innovative therapeutics. At Samaritan Pharmaceuticals our mission has been to create life-saving drugs for people suffering from AIDS, Alzheimer’s, heart disease and cancer. View all the latest press releases and news articles focused on Samaritan Pharmaceuticals, Inc. These publications, called peer-reviewed journals, are scholarly periodicals requiring each article submitted be judged by an independent panel of experts (scientific peers) to authenticate the accuracy of the material. The number of articles printed and the variety of publications accepting the article serve to underscore the legitimacy of information. Samaritan has collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovania, Syria and Turkey. Before a drug can be offered to the public it must go through several phases of rigorous testing to make sure it is safe, efficient and does what it says it can do. The testing is mandated and overseen by the U.S. Food and Drug Administration (FDA) which is part of the U.S. Department of Health and Human Services. SAMARITAN PIPELINE - (MECHANISM OF ACTION VIDEOS)
Go back to the main page. Contact Samaritan Pharmaceuticals, Inc. Find what you are looking for in our website.

EXECUTIVE PROFILES

Dr. Janet Greeson, Chairman, President and CEO, led the bold initiative that transformed Samaritan from a "one drug" Company to an innovative "Drug Development Pipeline" Biopharmaceutical Company. She strategically created a long-term value and growth model, with the Samaritan/Georgetown University collaboration; and intends to duplicate this growth model with other top tier Universities, as a solid strategy to continually build Samaritan's value and sustain its future profitability.

Dr. Greeson is a successful healthcare professional with over two decades of corporate experience focused on emerging growth situations, leadership development, and mergers and acquisitions. Although she has worked with Samaritan for nine years, as CEO for the past four years she has demonstrated a relentless perseverance and determination to succeed in the face of unrelenting change. She is extremely motivated and equipped to attack problems and seize realistic opportunities, with capability, courage and confidence.

Dr. Greeson is a co-inventor of 18 patent applications, and presently has nine "peer reviewed" journal publications. She is a best selling author of "It's Not What You Are Eating, It's What's Eating You"; and a renowned public speaker, whose guest appearances on numerous radio and TV Talk shows, has opened the door to tell the Samaritan story, in a concise and professional manner.

Dr. Greeson is an experienced growth "Model" developer. In the past, Dr. Greeson developed model "Addiction Rehab Programs" for the US Navy, and went on privately, to develop and grow a nationwide "inpatient treatment program model" which she later sold to Columbia/HCA (NYSE:COL).

Dr. Greeson has an eclectic past, once working with Mother Theresa and was privileged to be the U.S. Congressional Nominee for the State of Nevada in 1994, winning the primary without spending a dollar to campaign. She currently fulfills her altruistic energies with the Samaritan Innovative Science Foundation.

Dr. Greeson holds a BA, from Florida Technological University 1978; an MA from Rollins College 1979; a PhD from Columbia Pacific University 1987.

Dr. Greeson devotes substantially all of her time to the affairs of Samaritan Pharmaceuticals.

 

 

Finance

Eugene Boyle,
J.D., M.B.A.

Chief Financial Officer,
Business Development
USA

tel: 702.735.7001
fax: 702.737.7016

View Bio

Dianne Thompson, M.B.A.
Comptroller

tel: 702.735.7001
fax: 702.737.7016

View Bio


Drug Development

Dr. Tom Lang
Chief Drug Development Officer

tel: 702.735.7001
fax: 702.737.7016

View Bio

George Weaver
Regulatory Affairs

tel: 702.735.7001
fax: 702.737.7016

View Bio


Business Development

Kristi Eads, J.D.
V.P. Business Development / Out-Licensing
USA


tel: 702.735.7001
fax: 702.737.7016

View Bio
e-mail Kristi

Yannis S. Kalantzakis
Managing Director of Samaritan Pharmaceuticals Europe S.A
EUROPE


11 Fillopapou Street
11741 - Athens Greece
tel: +302109237890
fax:+302109237892

View Bio
e-mail Yannis

Barrie G. Fuller
Business Development

tel: 702.735.7001
fax: 702.737.7016

e-mail Barrie

   

Investor Relations


The Investor Relations Group

Investor Relations:

Adam Holdsworth, Erica Ruderman, Rachel Colgate
212.825.3210



Partnering
Opportunities